Safety profile: fifteen years of clinical experience with ibuprofen.
Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever. A careful review of pre-registration and postmarketing data from both patients and normal subjects clearly indicates ibuprofen's remarkable safety profile compared with that of aspirin and other commonly prescribed nonsteroidal anti-inflammatory agents. Continued safety can be anticipated on the basis of the past 15 years of review experience.
D000893:Anti-Inflammatory Agents / Q000633:toxicity; D001241:Aspirin / Q000633:toxicity; D001772:Blood Cell Count; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004361:Drug Tolerance; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007052:Ibuprofen / Q000633:toxicity*; D007674:Kidney Diseases / Q000139:chemically induced; D008111:Liver Function Tests; D014859:Warfarin / Q000097:blood
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D014859:Warfarin; D001241:Aspirin; D007052:Ibuprofen